AMICUS THERAPEUTICS, INC. Quarterly Income Tax Expense (Benefit) in USD from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Amicus Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2016 to Q3 2024.
  • Amicus Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $13.5M.
  • Amicus Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $36.3M.
  • Amicus Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $1.48M.
  • Amicus Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$5.47M, a 161% decline from 2021.
  • Amicus Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $8.91M, a 243% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $36.3M $13.5M +$16.6M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $19.7M $15.8M +$13.1M +482% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $6.61M $4.84M +$5.12M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $1.48M $2.18M +$16.4M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$14.9M -$3.13M -$7.15M -178% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$7.76M $2.72M +$1.8M +198% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$9.57M -$287K -$4.1M -108% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$5.47M -$14.2M -$17.2M -577% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $11.7M $4.02M +$4.21M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $7.52M $911K -$3.61M -79.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $11.1M $3.81M +$2.23M +141% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $8.91M $2.98M +$5.17M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $3.73M -$182K -$909K -125% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $4.64M $4.53M +$822K +22.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $3.82M $1.58M +$1.22M +338% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $2.6M -$2.19M -$2.04M -1306% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $4.64M $727K +$978K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $3.66M $3.7M +$2.99M +416% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $671K $361K +$193K +115% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $478K -$156K -$1.17M -115% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $1.64M -$251K -$200K -392% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.84M $717K +$378K +112% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $1.47M $168K +$1.56M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$94K $1.01M +$1.55M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$1.65M -$51K +$165M +100% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$166M $339K +$290K +592% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$167M -$1.39M -$1.45M -2586% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$165M -$541K Oct 1, 2017 Dec 31, 2017 10-K 2020-03-02
Q3 2017 -$165M -$164M -64992% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $49K +$502K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $56K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q3 2016 -$253K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$453K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.